Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

Stryker’s Minimally Invasive Acquisitions

by | Sep 15, 2016 6:28 pm | Medical Devices, Private Equity

For a company that has targeted minimally invasive surgical products of late, Stryker Corporation (NYSE: SYK) has been highly visible in the acquisition arena this year. It started in February 2016. That month, the medical device giant announced three deals, totaling $2.03 billion. In April, three more acquisitions were announced, with only one disclosed price of $40.6 million. Halfway through September, the company has made two more acquisitions, for undisclosed prices. For those keeping score, that’s eight deals for approximately $4.1 billion. Stryker’s most recent deals have targeted Ivy Sports Medicine, LLC for its minimally invasive meniscal repair platform, and Restore... Read More »

Allergan Eyes Clinical-Stage Ocular Drugs

by | Sep 14, 2016 8:45 am | Biotechnology, Pharmaceuticals

Allergan plc (NYSE: AGN) just purchased privately-held RetroSense Therapeutics LLC for $60 million in an all-cash transaction, with potential regulatory and commercialization milestone payments. Based in Ann Arbor Michigan, RetroSense is a clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in those suffering from blindness. Its lead development program, RST-001, is a novel gene therapy for the potential treatment of Retinitis Pigmentosa (RP). The acquisition gives Allergan global rights to RetroSense’s lead product candidate, RST-001. In 2014, RST-001 received Orphan Drug Designation by the U.S. FDA for the treatment of Retinitis... Read More »

Fresensius Helios Adds 43 Spanish Hospitals

by | Sep 13, 2016 8:04 am | Hospitals, Private Equity

Fresenius Helios (EXTRA: FRE.DE) was already the largest private hospital company in Europe, and now it’s grown even larger. On September 5, 2016, the company announced the acquisition of Quirónsalud, Spain’s largest private hospital operator, with 43 hospitals, 39 outpatient centers, and 300 occupational risk prevention centers.  Quirónsalud was created by the 2014 merger of IDC Salud and Grupo Hospitalario Quirón. Fresenius Helios, a division of Fresenius SE & Co. KGaA, vaulted to the top of the private European hospital market in September 2013, following the  its acquisition of 43 hospitals and 15 outpatient facilities in Germany, sold by Rhön Klinikum AG, for... Read More »

Stryker Corp. Makes Seventh Acquisition in 2016

by | Sep 9, 2016 3:23 pm | Medical Devices

Mergers and acquisitions in the medical device segment has been a bit sluggish this year. Even with two deals announced on September 1, marking 79th and 80th sector transactions in 2016, there is a lot of ground to make up to match the 114 deals announced in 2015. Stryker Corporation (NYSE: SYK) announced its seventh acquisition this year, paying an undisclosed amount for Ivy Sports Medicine, LLC. Ivy Sports Medicine provides medicine therapies for orthopedic surgeons and patients through its comprehensive minimally invasive meniscal repair platform. It includes the only FDA-approved collagen meniscus implant (CMI®) on the market. Ivy’s history and sole focus on advancing the... Read More »

Danaher Doubles Down on Blood Diagnostics

by | Sep 9, 2016 3:08 pm | Biotechnology

Danaher Corporation (NASDAQ: DHR) has set a new direction for itself, after spinning off its Test & Measurement segment, Industrial Technologies segment and its Retail/Commercial Petroleum platform into Fortive Corporation (NYSE: FTV) on July 2. Post-separation, the company is positioned as a global science and technology  innovator with more than 20 operating companies in the health care, environmental and industrial industries. In September, Danaher announced its acquisition of Cepheid (NASDAQ: CPHD ) for $3.9 billion, or $53.00 per share. The consideration represents approximately a 54% percent premium to Cepheid’s common stock over the closing price of $34.42 on September 2,... Read More »

The State of the Medical Marijuana Market

by | Sep 8, 2016 1:08 pm | Pharmaceuticals

In the 1960s and 70s, pot smokers were warned that marijuana could cause schizophrenia, among other mental disorders. Today, it’s lawmakers and government officials who exhibit symptoms of that condition. On August 11, 2016, the Drug Enforcement Administration (DEA) announced that it would allow more research into marijuana, and would expand the number of sites that can grow cannabis for research. At the same time, the agency rejected requests from several sectors, including The Epilepsy Foundation, that it relax the classification of cannabis from Schedule 1, as a dangerous, highly addictive drug with no medical use. Bummer, man. Today, 25 states have a medical or recreational cannabis... Read More »

Radiopharmacies Now on Dealmakers’ Radar

by | Sep 7, 2016 8:50 am | Other Services, Private Equity

You can’t get much more “specialty” in the specialty pharmacy business than to deal in radiopharmaceuticals. Two recent deals, announced in August, show this area is heating up. IBA Molecular, a global maker and distributor of radiopharmaceutical products, agreed to pay approximately $613 million for Mallinckrodt’s (NYSE: MNK) nuclear imaging business, including a portfolio of diagnostic imaging products. The U.S. market accounts for approximately two thirds of the division’s current annual revenues. For Mallinckrodt, the sale continues its strategic portfolio transformation, as the company evolves to handle specialty pharmaceuticals that don’t glow. IBA... Read More »

Third Quarter 2016 Shows Signs of Slowing

by | Sep 6, 2016 4:18 pm | Managed Care, Pharmaceuticals, Private Equity

Eight months into the year is a good time to take stock of the state of the healthcare M&A market. On the whole, volume and value look to be stronger than last year. The first eight months of 2016 show a combined total of 1,019 transactions, compared with 1,005 in the same period in 2015, a 1% difference. Five of the first eight months in 2016 have posted higher transaction totals than the same months in 2015. Deal values have to be examined more closely, owing to the mega-deals that can create huge month-to-month fluctuations. Total dollars spent in the first eight months of 2016 are approximately $196 billion. In the same period in 2015, spending reached nearly $338 billion, thanks... Read More »